GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » Gross Profit

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Gross Profit : $0.00 Mil (TTM As of Jun. 2018)


View and export this data going back to 2006. Start your Free Trial

What is EOM Pharmaceutical Holdings Gross Profit?

EOM Pharmaceutical Holdings's gross profit for the three months ended in Jun. 2018 was $0.00 Mil. EOM Pharmaceutical Holdings's gross profit for the trailing twelve months (TTM) ended in Jun. 2018 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. EOM Pharmaceutical Holdings's gross profit for the three months ended in Jun. 2018 was $0.00 Mil. EOM Pharmaceutical Holdings's Revenue for the three months ended in Jun. 2018 was $0.00 Mil. Therefore, EOM Pharmaceutical Holdings's Gross Margin % for the quarter that ended in Jun. 2018 was N/A%.

EOM Pharmaceutical Holdings had a gross margin of N/A% for the quarter that ended in Jun. 2018 => No sustainable competitive advantage


EOM Pharmaceutical Holdings Gross Profit Historical Data

The historical data trend for EOM Pharmaceutical Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings Gross Profit Chart

EOM Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

EOM Pharmaceutical Holdings Quarterly Data
Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of EOM Pharmaceutical Holdings's Gross Profit

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EOM Pharmaceutical Holdings's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's Gross Profit falls into.



EOM Pharmaceutical Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

EOM Pharmaceutical Holdings's Gross Profit for the fiscal year that ended in Dec. 2017 is calculated as

Gross Profit (A: Dec. 2017 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

EOM Pharmaceutical Holdings's Gross Profit for the quarter that ended in Jun. 2018 is calculated as

Gross Profit (Q: Jun. 2018 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

EOM Pharmaceutical Holdings's Gross Margin % for the quarter that ended in Jun. 2018 is calculated as

Gross Margin % (Q: Jun. 2018 )=Gross Profit (Q: Jun. 2018 ) / Revenue (Q: Jun. 2018 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


EOM Pharmaceutical Holdings  (OTCPK:IMUC) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

EOM Pharmaceutical Holdings had a gross margin of N/A% for the quarter that ended in Jun. 2018 => No sustainable competitive advantage


EOM Pharmaceutical Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Traded in Other Exchanges
N/A
Address
136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645
EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.
Executives
Andrew Gengos director 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus director, officer: Chairman and Secretary SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg director C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi director 246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin director C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell director 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender officer: VP, Product Development & Mfg. 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh director, officer: President & CEO 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne director 649 STONE CANYON ROAD, LOS ANGELES CA 90077

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Headlines